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Women who have had hypertension in pregnancy are at greater risk of long term 
cardiovascular disease (CVD). Little is known about their cardiovascular risk postpartum or 
the effects on the woman’s mental health and the outcomes of their infants. In this project 
we will study the physiological and psychological health of women and the physical health 
and development of their infants six months, two years and five years after birth. We will 
establish normal blood pressure (BP) ranges for women who were normotensive in 




Women will be asked to participate if they have given birth in the preceding six months. 
They will be excluded if they had diabetes, hypertension, renal or other serious maternal 
disease prior to pregnancy or congenital anomaly in the pregnancy. We will recruit 292 
women who were normotensive and their babies, 100 who had PE and 100 who had GH and 
their babies. They will be assessed at six months, two and five years after birth. At each 
assessment mothers will have their blood pressure (BP) assessed peripherally with a liquid 
crystal sphygmomanometer and 24 hour ambulatory blood pressure monitoring (ABPM), 
and centrally with non-invasive applanation tonometry. Additional physiological testing will 
include: body composition; energy balance; vascular compliance; cardiac function; liver and 
renal function, lipids and biochemistry; glucose and insulin; and urinalysis. Psychological 
status will be assessed with validated self-report questionnaires for depression, anxiety, 
posttraumatic stress disorder and mother-infant bonding. The babies will have a medical 
examination by a paediatrician at each assessment. Their behavioural development will be 
assessed with an Ages and Stages Questionnaire completed by their mother at each 
assessment and a developmental assessment by a child psychologist at two and five years. 
 
Conclusions: 
This study will re-define normal BP and other physiological parameters for young parous 
women thereby permitting a more sensitive assessment of post-partum BP and other 
cardiovascular risk markers in women who have had GH or PE. It will also determine the 
extent, if any, of psychological disorders in these women and developmental or other 
concerns in their babies. 
 
Trials Registration:  
Australian and New Zealand Clinical Trials Registry Number: ACTRN12613001260718 
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• Establishes a protocol for a prospective postpartum follow up study  
• Includes women who were normotensive and hypertensive in pregnancy and their 
babies 
• Incorporates Physiological and psychological assessment of mothers after defining 
new ‘normal ranges’ for women who have had normal pregnancies 
• Includes Physical and developmental assessment of their babies 
• Follow up at six months, two and five years postpartum 
 
Introduction: 
Hypertensive diseases in pregnancy are the most common medical complication of 
pregnancy affecting 10% of pregnant women [1]. GH is usually a benign condition with good 
maternal and fetal outcomes but 4% of pregnant women will develop PE, with increased 
maternal and fetal morbidity and mortality [2]. Cardiovascular disease is the leading cause 
of death for women in the western world [3]. Women who have had hypertension in 
pregnancy have a 2-3 fold increased risk of CVD in later life [4] and an increased risk for  
venous thromboembolism, diabetes, microalbuminuria, end stage renal disease [5] and 
mental health disorders [6]. The significant physiological demands of pregnancy are a stress 
test [7] that either unmasks a predisposition to CVD [8,9] or initiates a cascade of vascular 
changes which lead to later CVD [10]. 
 
Hypertension and Metabolic Syndrome after Hypertension in Pregnancy 
Subgroups of women with hypertension in pregnancy and CVD share the features of the 
metabolic syndrome including obesity, hypertension, insulin resistance and dyslipidaemia, 
and preeclampsia has been described as the metabolic syndrome of pregnancy [10]. This 
common risk pattern is relevant to clinical practice in that, although women with early onset 
PE (prior to 34 weeks gestation) have a greater risk of subsequent CVD [11] and end stage 
kidney disease [12], the features of the metabolic syndrome are more common in women 
with late onset PE (after 34 weeks gestation) or GH [13,14].  
 
Thus, women with any form of PE or even GH should be considered at risk for future CVD. 
The diagnosis of hypertension in pregnancy therefore provides a unique opportunity to 
identify a group of young women at risk of later disease and to institute measures to 
potentially lower their long term risk [15,16]. Interventional studies examining exercise and 
dietary modification in the postpartum period have been shown to be effective, particularly 
in women who know they are at increased risk [17,18]. However data are urgently needed 
to determine prevention strategies, screening and treatment schedules for the large 
number of women who have had hypertension in pregnancy [16]. Perhaps the biggest 
barrier to date is our need to rely on cardiovascular risk assessments that are designed for 
 
 
use in the general population, usually older people and often male predominant [19,20]. For 
example, we have shown previously that women who have had hypertension in pregnancy 
have higher BP several years post-partum than women who had a normotensive pregnancy 
[21]. Nonetheless their BP levels fall within the so-called ‘normal’ range and are therefore 
unlikely to be recognised as having a BP higher than that expected for a young woman who 
has had a previously normal pregnancy.  
 
What is needed is a study to define normal parameters for blood pressure and metabolic 
function in: 1) normal postpartum women; and 2) women who had hypertension in 
pregnancy; to determine where women who have had hypertension in pregnancy fall in 
newly defined ‘normal’ ranges. This is a major knowledge gap: there are no published data 
to provide guidance to clinicians. To the best of our knowledge this has not been done to 
date. Definition of the group of women at risk, i.e. falling outside newly defined normal 
parameters for this age group of women, would allow the establishment of a follow up 
guidance to coordinate early intervention for modification of lifestyle factors and treatment 
of hypertension and insulin resistance/diabetes [22,23].  
 
Psychological Issues after Hypertension in Pregnancy 
Our society generally assumes that the birth of a child should be an entirely positive 
experience. While on balance this is usually true, these expectations mean that women may 
find it difficult to discuss some of their negative experiences. This is important as childbirth 
can be difficult, with 20-48% of women reporting their birth experience as traumatic [24]. At 
one extreme, pregnancy complications and a difficult childbirth can lead to PTSD [25], 
although the exact prevalence of PTSD among new mothers is uncertain [26]. Not 
surprisingly, PTSD appears to be more common where there have been complications in 
pregnancy and/or the birth, such as PE [27] and co-existing maternal depression further 
increases the risk of PTSD [28].  
 
PTSD is one of a number of mental disorders that can be seen following a complicated 
pregnancy and birth. Increased levels of anxiety and depression have been reported 
amongst postpartum women, although it is not clear whether these symptoms develop 
during or after the pregnancy [5].  
 
Gaining a better understanding of the psychological consequences of complicated 
pregnancies is crucial for a number of reasons. Firstly, apart from the impact of these 
psychological disorders on the mother, maternal PTSD, anxiety and depression can affect 
the emotional and behavioural development of the infant and disturb mother-infant 
attachment [29]. Secondly, there is increasing evidence that if groups at high risk of mental 
disorder can be identified, targeted interventions can prevent around 25% of the cases of 
 
 
mental disorder occurring [30]. However, the success of such preventative interventions 
relies on a valid way of predicting those at increased risk. 
 
Paediatric Outcomes after Hypertension in Pregnancy 
While it is accepted that PE increases perinatal morbidity and mortality [2], the effects on 
the subsequent health and development of the infants of women who have had 
hypertension in pregnancy have not been adequately addressed. Variable findings have 
been reported [31,32] . Minor cognitive differences at two years of age were noted in 
infants of mothers with hypertension in pregnancy born at less than 35 weeks gestation [33] 
and a significant delay was reported in the children of women who had PE in a study of 
neurodevelopmental disability at two years of age [34]. In a study of developmental 
outcomes at two years of age in babies born at less than 32 weeks gestation, those infants 
whose mothers had PE were more likely to have mild cognitive impairment (OR 10.9, 95%CI 
1.4, 84.9) [35]. Similarly, in a small study of growth restricted babies (<5th centile) at three 
years of age, infants of mothers who had PE were more likely to have a moderately 
impaired cognitive development (mean IQ 85.5 vs. 96.9, p<0.03) [36]. However in a long 
term epidemiological study of recruits into the Israeli armed forces at 17 years of age there 
was no difference in mean intelligence scores between those whose mothers had PE and 
those who did not [37]. The study design is a longitudinal follow up of infants born to 
mothers with and without hypertension, which will provide sufficiently powered, controlled 
data to assess the effect of hypertension during pregnancy on growth and development, 
with adjustment for risk modifying variables, particularly gestational age.  
 
With this study we will define for the first time what should be considered normal BP 
(ABPM, routine office and central BP), lipids, heart and kidney function and mental health 
scores in young women who have had a normal pregnancy and the health of their babies. 
Similarly we will determine which women who were hypertensive in pregnancy and/or their 
babies who are at increased later risk.  
 
Methods/Design 
Study Design and Setting  
A prospective, open, cohort study is being undertaken at St George Hospital, a large 
metropolitan teaching hospital that serves an area of Sydney, Australia, with a diverse 
ethnic community.   
 
Hypotheses  
1. That women who have had hypertension in pregnancy:  
a. Have risk factors for CVD that are only recognised by comparison with a new 
‘normal’ range for blood pressure and other cardiovascular risk factors.  
b. Have a higher prevalence of psychological morbidity postpartum  
 
 
2. That the offspring of women who have had hypertension in pregnancy have a 
greater likelihood of abnormal growth and development six months after birth  
 
Outcomes  
1. The primary outcome is the prevalence of women in the formerly hypertensive 
groups with mean 24 hour systolic or diastolic BP two standard deviations greater 
than the mean BP derived from women who had normal pregnancies.  
2. Secondary outcomes are: (1) physiological measures: central BP, body composition, 
energy balance, cardiac function, renal function, lipids, insulin resistance (HOMA 
score) and urinalysis; (2) psychological measures: depression, anxiety, post-traumatic 
stress and mother-infant bonding; and (3) infant health: physical health and 
development.  
3. Development of guidance for the assessment, treatment and follow up of:  
a. Women who have increased risk factors for later CVD.  
b. Women who have psychological morbidity after hypertension in pregnancy.  
c. Children with physical or developmental impairment after maternal 
hypertension in pregnancy.  
 
Ethics Approval 
The study has been approved by the South Eastern Sydney Local Health District Human 
Research Ethics Committee (reference number: 12/195(HREC/12/POWH/395) 
 
 
Entry Criteria  
Women will be eligible if they have given birth to a live baby within six months and have a 
good understanding of written and spoken English. The babies born to these women will be 
included in the study. Women will be excluded if they had diabetes, hypertension, renal or 
other serious maternal disease prior to pregnancy, they had a multiple pregnancy, their 
baby was born with a congenital anomaly or they are pregnant again.  
 
Study Entry and Consent  
1. Women who are inpatients on the postnatal ward will be spoken to by the Research 
Midwife and given the Participant Information and Consent Form to read. If a woman 
agrees to participate in the study, written informed consent for the woman and her 
child will be obtained and an appointment made for the Six Month Assessment.  
2. Women who are discharged prior to meeting the Research Midwife will be mailed an 
Invitation to be Part of the Study letter and the Participant Information and Consent 
Form and a follow up phone call made. Written consent for the woman and her child 





Physiological measures - women 
1. Peripheral BP will be measured using a hybrid liquid crystal sphygmomanometer  
(mean of three readings) and ABPM, as the latter is known to more reliably predict 
long term CVD risk [38] and our previous work has shown subtle differences which 
would not have been detected with routine intermittent auscultation [21].  
2. Body composition will be determined by bio-impedance analysis [39], using a multi-
frequency body composition monitor (Fresenius Medical Care, Australia). This 
technique enables total body water volume, intra- and extracellular water, lean body 
mass and fat mass to be measured. These measures are relevant to hypertension 
and the metabolic syndrome. 
3. Energy balance will be determined by measuring total energy expenditure over 24 
hours using the SenseWear Armband (Temple Healthcare, Australia) which is worn 
for 24 hours, and measures skin temperature and heat flux. Participants will be asked 
to complete a three day food diary and the data will be entered into a Nutrient 
Calculation Program (Foodworks Version 1, Xyris Software Aust. Pty Ltd. Australia) 
enabling macronutrient dietary intake to be quantified. These measures will provide 
more detailed understanding of any differences between groups in body weight. 
4. Vascular wall stiffness and central BP will be determined using pulse wave analysis 
assessed with an applanation tonometer (Sphygmocor, AtCor Medical Pty Limited, 
Australia). Pulse wave analysis is performed over the radial artery, allowing non-
invasive measurement of central BP, detection of aortic stiffness and endothelial 
dysfunction. Endothelial dysfunction is an important component of the 
pathophysiology of PE and previous studies of pulse wave analysis in pregnancy have 
shown abnormalities in preeclamptic women [40,41]. However there are conflicting 
results on whether these persist into the postpartum period [42]. Measurement of 
vascular compliance is of increasing importance in the general hypertensive 
population and may become part of routine clinical practice in the near future [43]; 
hence it is important that we define normal for these parameters in this population.  
5. Cardiac function will be assessed with transthoracic 2-D echocardiography. Left 
ventricular (LV) systolic and diastolic function, LV wall thickness and fractional 
shortening will be measured as markers of cardiac dysfunction. Cardiac function is 
impaired in some women who have had a pregnancy complicated by hypertension, 
with persisting abnormal LV geometry and decreased diastolic function [44]. A single 
cardiologist will report all echocardiograms performed on women in the Study.  
6. Blood samples will be taken for full blood count, urea, electrolytes, creatinine and 
uric acid, liver function tests, magnesium, calcium, phosphate, fasting insulin and 
glucose, lipids (cholesterol, low and high density lipoproteins and triglycerides), and 
Vitamin D. An additional 20mL of blood will be separated and the serum and plasma 
stored at -80° C for later assay of sex hormone binding globulin, haemoglobin A1c, 
 
 
parathyroid hormone, adiponectin , leptin and angiotensin II receptor autoantibodies 
(implicated in the pathogenesis of PE [45]).  
7. A urine sample will be collected for automated dipstick urinalysis and laboratory 
testing for albumin, protein and creatinine. Blood and urine testing of these 
parameters will determine whether subtle abnormalities of renal function, vitamin D 




The assessment of women’s psychological health will be made using validated self-report 
questionnaires. Participants will be asked to complete the Edinburgh Postnatal Depression 
Scale (EPDS) [46], the General Anxiety Disorder 7-item scale (GAD-7) [47] and the 
Posttraumatic Diagnostic Scale (PDS) [48]. The EPDS is a 10 item measure designed to screen 
women for symptoms of emotional distress during pregnancy and the postnatal period 
which has been validated in Australian women [49]. The GAD-7 is a well validated tool for 
detecting Generalised Anxiety Disorder, the most common, non-phobic anxiety disorder in a 
post-natal population, while the PDS is a 49 item scale that enquires about the key 
diagnostic criteria of post-traumatic stress disorder. In addition, maternal infant bonding 
will be assessed using the self-report Maternal Infant Bonding (MIB) questionnaire [50].  
 
Infant Assessment 
 The infant’s development will be assessed using the Ages and Stages Questionnaire (ASQ) 
that is within one month of their child’s age, corrected for the infant’s gestation at birth 
[52]. This is a short questionnaire regarding the child’s development that the mother or 
care-giver completes. A full history and physical examination performed by a specialist 
Paediatrician will determine the presence of any chronic illness, and elicit information on 
hospital admissions. Height, weight and head circumference will be plotted on World Health 
Organisation charts and standard deviation scores determined. Blood pressure will be 
measured using an appropriately sized paediatric cuff on an automated 
sphygmomanometer. 
 
Assessment Schedule  
1. Six Months: initial assessment of mothers and babies will occur at six months 
postpartum. This time was chosen as the maternal physiology and psychology will 
have returned to normal after pregnancy, babies will usually have recovered from 
any illness related to the birth and mothers are more likely to be compliant in 
attending for assessment.  
2. Two Years: mothers and babies will be assessed at two years to assess medium term 
outcomes and that the risk assessment at six months postpartum has been accurate. 
 
 
By two years of age subtle physical and developmental impairment in the infants will 
be more apparent.  
3. Five Years: the development of CVD is a long term health risk. Although it is unlikely 
that there will be overt evidence of CVD at five years, this was deemed to be a 
realistic long term assessment of the outcomes of mothers and infants.  
 
Six Month Assessment  
Women recruited to the study will be asked to attend six months after birth. Prior to this 
they are sent, and asked to complete, an ASQ corrected for prematurity. Written consent 
will be obtained at this visit for them and their baby to take part in the study if not already 
completed.  
Data Collection  
1. History  
Demographics: age, ethnicity, relationship status, highest educational level, 
occupations of mother and father  
Medical: history of infertility and fertility treatment, psychiatric history, significant 
illness, diabetes, smoking, renal disease  
Family: history of hypertension, CVD, diabetes  
Obstetric: diagnosis of GH or PE, gestation at diagnosis, antihypertensive medication 
score, labour onset, gestation at birth, pain relief in labour, mode of birth, 
MgSO4 given, episodes of severe hypertension, postpartum complications  
2. Measurements  
Weight, height, and ratio of waist:hip circumference  
Blood pressure - average of three measurements using a hybrid sphygmomanometer  
Vascular wall stiffness using Sphygmocor applanation tonometer  
Body composition using body composition monitor  
Blood and urine testing  
3. Psychological testing  
Self-report questionnaires - EPDS, PDS, GAD-7, MIB scales  
 
Follow up appointments  
Follow up will be arranged for the collection of the food diary and ABPM and appointments 
for the SenseWear Armband and food diary, echocardiogram and the visit to the 
Paediatrician.  
Cardiac Function  
Echocardiography will be performed at a separate appointment. The parameters 
measured will be: LV geometry including wall thickness, regional wall thickness and 
LV mass index, diastolic parameters, and global longitudinal strain. All reporting of 





Two and Five Year Assessments  
All mothers seen for Six Month Assessments will be contacted at 6, 12 and 18 months by a 
member of the P4 Study team to confirm their current residential address and document 
any changes of contact details for themselves and the contact people they provide at trial 
entry. Appointments will be made for participants at two and five years postpartum. An age 
appropriate ASQ will be posted for the mother to complete prior to the visit.  
 
All physiological and psychological testing will be repeated as in the Six Month Assessment 
visit. An appointment will be made for children in the study to be examined by the 
paediatrician and a Child Developmental Psychologist at two and five years. The 
psychologist will carry out a Bayley III assessment [52] at two years and full developmental 
assessment at five years to determine the child’s development in the areas of cognitive, 
language and communication, and both fine and gross motor skills.  
 
Management of abnormal findings  
With consent, a summary of the study results will be sent to the woman’s family doctor 
highlighting abnormal findings. If abnormalities are detected the woman will be contacted 
and advised to visit her doctor. Referral to Mental Health Services will be offered for 
abnormal score/s on any of the mental health questionnaires. 
 
Sample Size  
The study will be powered on the proportion of average 24 hour average diastolic blood 
pressure (DBP) readings two or more standard deviations (SD) above the mean for women 
who were normotensive in pregnancy. In preliminary data on normotensive women at six 
months postpartum, 4/98 (4%) had 24 hour average DBP readings > 2 SD above the mean, 
as expected, compared to 5/22 (23%) hypertensive women. Based on these data, 56 women 
will be required in each group, with a 95% confidence level and 85% power. Sample size 
assessment is based on the hypertensive group as a whole but current data suggests that 
the women who had PE and GH have similar rates of elevated average 24 hour DBP.  
We plan to recruit 292 women who were normotensive in pregnancy in order to construct a 
95% reference range [53] for normal values in a postpartum population. One hundred 
women who had GH and 100 who had PE in pregnancy will be recruited. This will allow for 
an estimated 15% loss to follow up and women who will be pregnant again prior to two year 
and five year follow ups. Women who have been pregnant again prior to follow up at two 
and five years will be analysed on intention-to-treat with subgroup analysis.  
 
Data Analysis  
Initial analyses of the two groups will be descriptive, and the appropriate Chi-squared test 
used for categorical data and Student’s t-test for continuous data when normally 
 
 
distributed. More sophisticated analyses will include, where relevant, the use of (i) 
generalised linear models to evaluate the effects of covariates and their interactions, and (ii) 
the method of generalised estimating equations to accommodate the repeated measures as 




ABPM is currently the gold standard for BP measurement and a key determinant of 
cardiovascular risk [38]. The primary outcome of the study is the mean 24 hour diastolic BP 
at six months postpartum as a surrogate marker for long term risk of CVD. We will recruit 
292 women who were normotensive in pregnancy to define normal values and ranges for all 
parameters. We will assess of 100 women who had GH and 100 with PE in their pregnancy 
to determine the frequency of abnormal findings in these women and their babies. Of great 
importance, it will also allow us to reassure those women who are not at long term risk of 
CVD.  
 
This study is of significant clinical and public health importance because of the recently 
recognised long term cardiovascular and mental health consequences of women who have 
had hypertensive disease in pregnancy. There are no comparable follow up studies of 
women and their babies underway, nationally or internationally. In particular, clinicians 
presently do not have an upper limit of normal for cardiovascular risk or psychological 
parameters in young women who have had a normal pregnancy; we rely upon ‘normal’ 
values for parameters such as BP that have been derived from the general, often older, 
population. At the end of this study we will define for the first time in young women who 
have had a normal pregnancy what should be considered normal BP (by ABPM, routine 
office and central BP measures), blood lipids, heart and kidney function and mental health 
scores and the health of their babies. Our ultimate goal is to establish follow up guidance for 
women who have had hypertension in pregnancy and their babies, with the guidance 
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